BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K, Gorgun G, Relias V, Grodman H, Mahajan A. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant. 2004;33:881-889. [PMID: 14990986 DOI: 10.1038/sj.bmt.1704454] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Souchet L, Masouridi S, Marçais A, Ibrahim A, Chauvel C, Turquet E, Derail M, Yakoub-agha I, Crocchiolo R. Diagnostic, prophylaxie et prise en charge thérapeutique de la GVH aiguë : recommandations de la Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bulletin du Cancer 2022. [DOI: 10.1016/j.bulcan.2022.11.001] [Reference Citation Analysis]
2 Kaynar L, Tekgunduz E, Kozanoglu I, Ozkan HA, Demirkan F, Ozkalemkas F. Extracorporeal photopheresis in the treatment for acute and chronic graft-versus-host disease: a position statement from The Turkish Society of Apheresis (TSA). Transfusion and Apheresis Science 2022. [DOI: 10.1016/j.transci.2022.103373] [Reference Citation Analysis]
3 Abdelhakim H, Accurso A, Merkel D, Dejarnette S, Aljitawi O, Yankee T, He J, Ganguly S, McGuirk J, Abhyankar S. Peri-transplant extracorporeal photopheresis to mitigate GVHD- a pilot clinical trial. Bone Marrow Transplant 2021;56:980-2. [PMID: 33219342 DOI: 10.1038/s41409-020-01142-4] [Reference Citation Analysis]
4 Knobler R, Arenberger P, Arun A, Assaf C, Bagot M, Berlin G, Bohbot A, Calzavara-Pinton P, Child F, Cho A, French LE, Gennery AR, Gniadecki R, Gollnick HPM, Guenova E, Jaksch P, Jantschitsch C, Klemke C, Ludvigsson J, Papadavid E, Scarisbrick J, Schwarz T, Stadler R, Wolf P, Zic J, Zouboulis C, Zuckermann A, Greinix H. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1. J Eur Acad Dermatol Venereol 2020;34:2693-716. [PMID: 33025659 DOI: 10.1111/jdv.16890] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
5 Foss FM, Wang XV, Luger SM, Jegede O, Miller KB, Stadtmauer EA, Whiteside TL, Avigan DE, Gascoyne RD, Arber D, Wagner H, Strair RK, Hogan WJ, Sprague KA, Lazarus HM, Litzow MR, Tallman MS, Horning SJ. Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. Transfusion 2020;60:1867-72. [PMID: 32654201 DOI: 10.1111/trf.15798] [Reference Citation Analysis]
6 Isufi I, Seropian S, Gowda L, Wilson LD, Roberts K, Girardi M, Perreault S, Foss F. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma 2020;61:2955-61. [DOI: 10.1080/10428194.2020.1790555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
7 Drexler B, Buser A, Infanti L, Stehle G, Halter J, Holbro A. Extracorporeal Photopheresis in Graft-versus-Host Disease. Transfus Med Hemother 2020;47:214-25. [PMID: 32595426 DOI: 10.1159/000508169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
8 Hölig K, Greinix H. Extracorporeal Photopheresis in Hematopoietic Cell Transplantation. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy 2020. [DOI: 10.1007/978-3-319-55131-9_13] [Reference Citation Analysis]
9 Chaulagain CP, Sprague KA, Pilichowska M, Cowan J, Klein AK, Kaul E, Miller KB. Clinicopathologic characteristics of secondary squamous cell carcinoma of head and neck in survivors of allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 2019;54:560-6. [PMID: 30127467 DOI: 10.1038/s41409-018-0299-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
10 Schneiderman J. Extracorporeal photopheresis: cellular therapy for the treatment of acute and chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2017;2017:639-44. [PMID: 29222315 DOI: 10.1182/asheducation-2017.1.639] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
11 Abutalib SA, Lazarus HM. Special Care of Blood and Marrow Hematopoietic Cell Transplant Recipient. Neoplastic Diseases of the Blood 2018. [DOI: 10.1007/978-3-319-64263-5_57] [Reference Citation Analysis]
12 Choe HK, van Besien K. Earlier may be better: the role of extracorporeal photopheresis (ECP) as prevention of GVHD after allogeneic transplant. Leuk Lymphoma 2018;59:272-3. [PMID: 28812411 DOI: 10.1080/10428194.2017.1361034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
13 Michallet M, Sobh M, Garban F, Bulabois CE, Yakoub-Agha I, Coiteux V, Dulery R, Rohrlich PS, Legrand F, Clement L, Praire A, Detrait M, Barraco F, Nicolini FE, Hequet O. Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study. Leuk Lymphoma 2018;59:372-80. [PMID: 28587506 DOI: 10.1080/10428194.2017.1334120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
14 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
15 Wong JY, Schultheiss T. Radiotherapeutic Principles of Hematopoietic Cell Transplantation. Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch22] [Reference Citation Analysis]
16 Kitko CL, Braun T, Couriel DR, Choi SW, Connelly J, Hoffmann S, Goldstein S, Magenau J, Pawarode A, Reddy P, Schuler C, Yanik GA, Ferrara JL, Levine JE. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant 2016;22:862-8. [PMID: 26551636 DOI: 10.1016/j.bbmt.2015.11.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
17 Mossoba ME, Halverson DC, Kurlander R, Schuver BB, Carpenter A, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche J, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Khuu H, Sabatini M, Stroncek D, Levine BL, June CH, Mariotti J, Rixe O, Fojo AT, Bishop MR, Gress RE, Fowler DH. High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clin Cancer Res 2015;21:4312-20. [PMID: 26071480 DOI: 10.1158/1078-0432.CCR-15-0340] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kitko CL, Levine JE. Extracorporeal photopheresis in prevention and treatment of acute GVHD. Transfus Apher Sci 2015;52:151-6. [PMID: 25748231 DOI: 10.1016/j.transci.2015.02.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
19 Fowler DH, Halverson DC. Rapamycin-Resistant T Cells and Pentostatin-Based Immuno-Selective Conditioning for the Allogeneic T Cell Therapy of Cancer. Cancer Drug Discovery and Development 2015. [DOI: 10.1007/978-3-319-21167-1_13] [Reference Citation Analysis]
20 Knobler R, Berlin G, Calzavara-Pinton P, Greinix H, Jaksch P, Laroche L, Ludvigsson J, Quaglino P, Reinisch W, Scarisbrick J, Schwarz T, Wolf P, Arenberger P, Assaf C, Bagot M, Barr M, Bohbot A, Bruckner-Tuderman L, Dreno B, Enk A, French L, Gniadecki R, Gollnick H, Hertl M, Jantschitsch C, Jung A, Just U, Klemke CD, Lippert U, Luger T, Papadavid E, Pehamberger H, Ranki A, Stadler R, Sterry W, Wolf IH, Worm M, Zic J, Zouboulis CC, Hillen U. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 2014;28 Suppl 1:1-37. [PMID: 24354653 DOI: 10.1111/jdv.12311] [Cited by in Crossref: 138] [Cited by in F6Publishing: 139] [Article Influence: 15.3] [Reference Citation Analysis]
21 Bethge WA, Kerbauy FR, Santos EB, Gooley T, Storb R, Sandmaier BM. Extracorporeal photopheresis combined with pentostatin in the conditioning regimen for canine hematopoietic cell transplantation does not prevent GVHD. Bone Marrow Transplant 2014;49:1198-204. [PMID: 25046213 DOI: 10.1038/bmt.2014.137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
22 Florek M, Sega EI, Leveson-Gower DB, Baker J, Müller AM, Schneidawind D, Meyer E, Negrin RS. Autologous apoptotic cells preceding transplantation enhance survival in lethal murine graft-versus-host models. Blood 2014;124:1832-42. [PMID: 25030062 DOI: 10.1182/blood-2014-02-555128] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
23 Rutella S, Valentini CG, Ceccarelli S, Romano MT, Brescia LP, Milano GM, Locatelli F. Extracorporeal photopheresis for paediatric patients experiencing graft-versus-host disease (GVHD). Transfusion and Apheresis Science 2014;50:340-8. [DOI: 10.1016/j.transci.2014.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
24 Liesveld JL, Phillips GL 2nd, Becker M, Constine LS, Friedberg J, Andolina JR, Milner LA, DeBolt J, Smudzin T, Hyrien O, Erickson-Miller CL, Johnson BM, Dawson KL, Chen Y. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2013;19:1745-52. [PMID: 24120380 DOI: 10.1016/j.bbmt.2013.10.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
25 Yu ZP, Ding JH, Chen BA, Li YF, Ding BH, Qian J. An anti-human thymocyte globulin-based reduced-intensity conditioning regimen is associated with a higher quality of life and lower organ toxicity without affecting lymphocyte reconstitution. PLoS One 2013;8:e73755. [PMID: 24040055 DOI: 10.1371/journal.pone.0073755] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Hashmi S, Oliva JL, Liesveld JL, Phillips GL, Milner L, Becker MW. The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. Leukemia Research 2013;37:1052-6. [DOI: 10.1016/j.leukres.2013.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
27 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;:CD008908. [PMID: 23986525 DOI: 10.1002/14651858.CD008908.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
28 Kharfan-Dabaja MA, Anasetti C, Fernandez HF, Perkins J, Ochoa-Bayona JL, Pidala J, Perez LE, Ayala E, Field T, Alsina M, Nishihori T, Locke F, Pinilla-Ibarz J, Tomblyn M. Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. Biol Blood Marrow Transplant 2013;19:1087-93. [PMID: 23632090 DOI: 10.1016/j.bbmt.2013.04.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
29 Lazarus HM, Arfons LM, Creger RJ. Special Care of Blood and Marrow Stem Transplant Patients. Neoplastic Diseases of the Blood 2013. [DOI: 10.1007/978-1-4614-3764-2_59] [Reference Citation Analysis]
30 Kaloyannidis P, Mallouri D. The role of the extracorporeal photopheresis in the management of the graft-versus-host disease. Transfusion and Apheresis Science 2012;46:211-9. [DOI: 10.1016/j.transci.2011.10.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
31 Mossoba ME, Onda M, Taylor J, Massey PR, Treadwell S, Sharon E, Hassan R, Pastan I, Fowler DH. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res 2011;17:3697-705. [PMID: 21521777 DOI: 10.1158/1078-0432.CCR-11-0493] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
32 Bethge WA, Kerbauy FR, Santos E, Gooley TA, Storb R, Sandmaier BM. Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment. Bone Marrow Transplant 2011;46:1382-8. [PMID: 21151184 DOI: 10.1038/bmt.2010.301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
33 Mariotti J, Taylor J, Massey PR, Ryan K, Foley J, Buxhoeveden N, Felizardo TC, Amarnath S, Mossoba ME, Fowler DH. The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. Biol Blood Marrow Transplant 2011;17:620-31. [PMID: 21130889 DOI: 10.1016/j.bbmt.2010.11.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
34 Poutsiaka DD, Munson D, Price LL, Chan GW, Snydman DR. Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated. Bone Marrow Transplant 2011;46:300-7. [PMID: 20479711 DOI: 10.1038/bmt.2010.112] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 5.4] [Reference Citation Analysis]
35 Cutler C, Ho VT, Antin JH. Acute Graft Versus Host Disease: Prophylaxis. Allogeneic Stem Cell Transplantation 2010. [DOI: 10.1007/978-1-59745-478-0_32] [Reference Citation Analysis]
36 Goldstein SC, Luger S. Concepts and Controversies in the Use of Novel Preparative Regimens for Allogeneic Stem Cell Transplantation. In: Lazarus HM, Laughlin MJ, editors. Allogeneic Stem Cell Transplantation. Totowa: Humana Press; 2010. pp. 441-58. [DOI: 10.1007/978-1-59745-478-0_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, Horowitz MM, Abhyankar S. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2010;45:1068-76. [PMID: 19915634 DOI: 10.1038/bmt.2009.307] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
38 Maeda A, Schwarz A, Bullinger A, Morita A, Peritt D, Schwarz T. Experimental extracorporeal photopheresis inhibits the sensitization and effector phases of contact hypersensitivity via two mechanisms: generation of IL-10 and induction of regulatory T cells. J Immunol. 2008;181:5956-5962. [PMID: 18941184 DOI: 10.4049/jimmunol.181.9.5956] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 4.8] [Reference Citation Analysis]
39 Chaballa M, Filicko-o'hara J, Holt D, Frank AM, Wagner JL, Grosso D, Flomenberg N. TRANSPLANT MEDICINE. Pharmacology and Therapeutics 2009. [DOI: 10.1016/b978-1-4160-3291-5.50096-2] [Reference Citation Analysis]
40 Foss F, van Besien K. Reduced-Intensity and Nonmyeloablative Conditioning Regimens. Cancer Treatment and Research 2009. [DOI: 10.1007/978-0-387-78580-6_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
41 Lekakis L, de Lima M. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia. Expert Rev Anticancer Ther 2008;8:785-98. [PMID: 18471050 DOI: 10.1586/14737140.8.5.785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
42 Scarisbrick J, Taylor P, Holtick U, Makar Y, Douglas K, Berlin G, Juvonen E, Marshall S; on behalf of the Photopheresis Expert Group. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 2008;158:659-78. [DOI: 10.1111/j.1365-2133.2007.08415.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 129] [Article Influence: 8.5] [Reference Citation Analysis]
43 Kovalszki A, Schumaker GL, Klein A, Terrin N, White AC. Reduced respiratory and skeletal muscle strength in survivors of sibling or unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41:965-9. [PMID: 18264142 DOI: 10.1038/bmt.2008.15] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
44 Nedelcu E, Ziman A, Fernando LP, Cook K, Bumerts P, Schiller G. Exclusive use of acid citrate dextrose for anticoagulation during extracorporeal photopheresis in patients with contraindications to heparin: An effective protocol. J Clin Apheresis 2008;23:66-73. [DOI: 10.1002/jca.20159] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
45 Carcagnì MR, De Aloe G, D'Ascenzo G, Rubegni P, Fimiani M. Extracorporeal photopheresis in graft-versus-host disease. J Dtsch Dermatol Ges 2008;6:451-7. [PMID: 18177413 DOI: 10.1111/j.1610-0387.2007.06591.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
46 Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008;26:577-84. [PMID: 18086801 DOI: 10.1200/JCO.2007.11.1641] [Cited by in Crossref: 173] [Cited by in F6Publishing: 180] [Article Influence: 10.8] [Reference Citation Analysis]
47 Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis. 2007;2:35. [PMID: 17784964 DOI: 10.1186/1750-1172-2-35] [Cited by in Crossref: 144] [Cited by in F6Publishing: 153] [Article Influence: 9.0] [Reference Citation Analysis]
48 Poutsiaka DD, Price LL, Ucuzian A, Chan GW, Miller KB, Snydman DR. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant. 2007;40:63-70. [PMID: 17468772 DOI: 10.1038/sj.bmt.1705690] [Cited by in Crossref: 145] [Cited by in F6Publishing: 154] [Article Influence: 9.1] [Reference Citation Analysis]
49 Subramaniam DS, Fowler DH, Pavletic SZ. Chronic graft-versus-host disease in the era of reduced-intensity conditioning. Leukemia. 2007;21:853-859. [PMID: 17377592 DOI: 10.1038/sj.leu.2404642] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
50 Marshall SR. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006;3:302-14. [PMID: 16757968 DOI: 10.1038/ncponc0511] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 4.8] [Reference Citation Analysis]
51 Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006;20:1673-82. [PMID: 16871280 DOI: 10.1038/sj.leu.2404328] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
52 Foss FM. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Semin Hematol 2006;43:S35-43. [PMID: 16549113 DOI: 10.1053/j.seminhematol.2005.12.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
53 Higman M, Vogelsang GB, Chen A. Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother 2004;5:2605-13. [PMID: 15571477 DOI: 10.1517/14656566.5.12.2605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
54 Griffith LM, Pavletic SZ, Tyndall A, Bredeson CN, Bowen JD, Childs RW, Gratwohl A, van Laar JM, Mayes MD, Martin R, Mcsweeney PA, Muraro PA, Openshaw H, Saccardi R, Sandmaier BM, Forman SJ, Nash RA. Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute–Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biology of Blood and Marrow Transplantation 2005;11:862-70. [DOI: 10.1016/j.bbmt.2005.07.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 2.5] [Reference Citation Analysis]
55 Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, Zeng C, Baron A, McSweeney PA. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplant 2005;36:443-51. [PMID: 15995712 DOI: 10.1038/sj.bmt.1705081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
56 White AC, Terrin N, Miller KB, Ryan HF. Impaired Respiratory and Skeletal Muscle Strength in Patients Prior to Hematopoietic Stem-Cell Transplantation. Chest 2005;128:145-52. [DOI: 10.1378/chest.128.1.145] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 2.6] [Reference Citation Analysis]
57 Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2005;130:256-64. [DOI: 10.1111/j.1365-2141.2005.05600.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
58 Bolaños-meade J, Jacobsohn DA, Margolis J, Ogden A, Wientjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever MR, Vogelsang GB. Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease. JCO 2005;23:2661-8. [DOI: 10.1200/jco.2005.06.130] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 5.3] [Reference Citation Analysis]
59 Kanold J, Messina C, Halle P, Locatelli F, Lanino E, Cesaro S, Deméocq F; on behalf of the Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Update on extracorporeal photochemotherapy for graft-versus-host disease treatment. Bone Marrow Transplant 2005;35:S69-71. [DOI: 10.1038/sj.bmt.1704851] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
60 Devetten MP, Vose JM. Graft-versus-host disease: How to translate new insights into new therapeutic strategies. Biology of Blood and Marrow Transplantation 2004;10:815-25. [DOI: 10.1016/j.bbmt.2004.10.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]